Amneal Pharmaceuticals, Inc. (AMRX)

Market Cap	613.12M
Revenue (ttm)	2.12B
Net Income (ttm)	-133.58M
Shares Out	303.52M
EPS (ttm)	0.01
PE Ratio	202.00
Forward PE	6.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	756,102
Open	2.10
Previous Close	2.09
Day's Range	2.02 - 2.14
52-Week Range	2.00 - 5.99
Beta	1.32
Analysts	Buy
Price Target	5.92 (+193.1%)
Earnings Date	Nov 1, 2022

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in ...

• Industry: Pharmaceuticals
• Founded: 2002
• Employees: 7,000
• Stock Exchange: NYSE
• Ticker Symbol: AMRX

Full Company Profile

Financial Performance

In 2021, AMRX's revenue was $2.09 billion, an increase of 5.08% compared to the previous year's $1.99 billion. Earnings were $10.62 million, a decrease of -88.33%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price forecast is 5.92, which is an increase of 193.07% from the latest price.

Price Target

$5.92

(193.07% upside)

Analyst Consensus: Buy

Stock Forecasts